SI2139479T1 - 4-(2-(4-metilfenilsulfanil)fenil)piperidin s kombinirano serotonin in norepinefrin reuptake inhibicijo za zdravljenje adhd melanholije, zdravljenje resistentne depresije ali preostalih simptomov pri depresiji - Google Patents

4-(2-(4-metilfenilsulfanil)fenil)piperidin s kombinirano serotonin in norepinefrin reuptake inhibicijo za zdravljenje adhd melanholije, zdravljenje resistentne depresije ali preostalih simptomov pri depresiji

Info

Publication number
SI2139479T1
SI2139479T1 SI200830877T SI200830877T SI2139479T1 SI 2139479 T1 SI2139479 T1 SI 2139479T1 SI 200830877 T SI200830877 T SI 200830877T SI 200830877 T SI200830877 T SI 200830877T SI 2139479 T1 SI2139479 T1 SI 2139479T1
Authority
SI
Slovenia
Prior art keywords
depression
treatment
phenylcpiperidine
methylphenylsulfanyl
melancholia
Prior art date
Application number
SI200830877T
Other languages
English (en)
Inventor
Tine Bryan Stensbol
Silke Miller
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of SI2139479T1 publication Critical patent/SI2139479T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SI200830877T 2007-03-20 2008-03-14 4-(2-(4-metilfenilsulfanil)fenil)piperidin s kombinirano serotonin in norepinefrin reuptake inhibicijo za zdravljenje adhd melanholije, zdravljenje resistentne depresije ali preostalih simptomov pri depresiji SI2139479T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
EP08715618A EP2139479B1 (en) 2007-03-20 2008-03-14 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
PCT/DK2008/050064 WO2008113360A2 (en) 2007-03-20 2008-03-14 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression

Publications (1)

Publication Number Publication Date
SI2139479T1 true SI2139479T1 (sl) 2013-04-30

Family

ID=39575680

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830877T SI2139479T1 (sl) 2007-03-20 2008-03-14 4-(2-(4-metilfenilsulfanil)fenil)piperidin s kombinirano serotonin in norepinefrin reuptake inhibicijo za zdravljenje adhd melanholije, zdravljenje resistentne depresije ali preostalih simptomov pri depresiji

Country Status (27)

Country Link
US (2) US20100144788A1 (sl)
EP (2) EP2139479B1 (sl)
JP (1) JP5388867B2 (sl)
KR (1) KR20090125775A (sl)
CN (2) CN101674830B (sl)
AR (1) AR065798A1 (sl)
AU (1) AU2008228639B2 (sl)
BR (1) BRPI0808831A2 (sl)
CA (1) CA2684556C (sl)
CL (1) CL2008000796A1 (sl)
CO (1) CO6220957A2 (sl)
CY (2) CY1113965T1 (sl)
DK (2) DK2139479T3 (sl)
EA (1) EA017407B1 (sl)
ES (2) ES2399305T3 (sl)
HR (1) HRP20130049T1 (sl)
IL (1) IL200954A (sl)
MX (1) MX2009009934A (sl)
MY (1) MY163537A (sl)
NZ (1) NZ579723A (sl)
PL (2) PL2139479T3 (sl)
PT (2) PT2139479E (sl)
RS (2) RS52676B (sl)
SI (1) SI2139479T1 (sl)
TW (1) TWI432194B (sl)
UA (2) UA97660C2 (sl)
WO (1) WO2008113360A2 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110412T1 (hr) * 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
WO2008151632A1 (en) * 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
EP2564837B1 (en) * 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
US8745134B1 (en) 2011-03-04 2014-06-03 Zynga Inc. Cross social network data aggregation
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004539B1 (ru) * 1998-05-22 2004-06-24 Эли Лилли Энд Компани Комбинационная терапия для лечения резистентной депрессии
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
JP2006522027A (ja) * 2003-04-04 2006-09-28 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルオキシフェニル）−ピペリジンまたは−１，２，３，６−テトラヒドロピリジン誘導体
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
HRP20110412T1 (hr) * 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
CN101674830B (zh) 2012-05-09
CO6220957A2 (es) 2010-11-19
CN101674830A (zh) 2010-03-17
AU2008228639B2 (en) 2012-12-13
CN101646438B (zh) 2012-04-11
HK1142007A1 (en) 2010-11-26
PL2139479T3 (pl) 2013-05-31
MY163537A (en) 2017-09-15
EA200970871A1 (ru) 2010-04-30
HRP20130049T1 (hr) 2013-02-28
PT2139479E (pt) 2013-02-20
UA99611C2 (ru) 2012-09-10
RS53138B (sr) 2014-06-30
CY1114774T1 (el) 2016-12-14
WO2008113360A3 (en) 2008-11-13
EP2167085A1 (en) 2010-03-31
IL200954A0 (en) 2010-05-17
CY1113965T1 (el) 2016-07-27
CA2684556C (en) 2013-01-08
BRPI0808831A2 (pt) 2014-08-26
TW200848032A (en) 2008-12-16
EP2139479A2 (en) 2010-01-06
AU2008228639A1 (en) 2008-09-25
CA2684556A1 (en) 2008-09-25
US20100137366A1 (en) 2010-06-03
EA017407B1 (ru) 2012-12-28
TWI432194B (zh) 2014-04-01
UA97660C2 (ru) 2012-03-12
WO2008113360A2 (en) 2008-09-25
DK2139479T3 (da) 2013-02-11
MX2009009934A (es) 2009-09-24
PL2167085T3 (pl) 2014-08-29
DK2167085T3 (da) 2014-02-03
CL2008000796A1 (es) 2008-09-26
NZ579723A (en) 2011-07-29
AR065798A1 (es) 2009-07-01
CN101646438A (zh) 2010-02-10
KR20090125775A (ko) 2009-12-07
PT2167085E (pt) 2014-02-17
US20100144788A1 (en) 2010-06-10
RS52676B (sr) 2013-06-28
EP2139479B1 (en) 2012-12-12
JP5388867B2 (ja) 2014-01-15
JP2010521502A (ja) 2010-06-24
IL200954A (en) 2014-12-31
ES2445400T3 (es) 2014-03-03
US8507526B2 (en) 2013-08-13
EP2167085B1 (en) 2013-12-25
ES2399305T3 (es) 2013-03-27

Similar Documents

Publication Publication Date Title
SI2139479T1 (sl) 4-(2-(4-metilfenilsulfanil)fenil)piperidin s kombinirano serotonin in norepinefrin reuptake inhibicijo za zdravljenje adhd melanholije, zdravljenje resistentne depresije ali preostalih simptomov pri depresiji
EP2758364A4 (en) AZEOTROP-SIMILAR COMPOSITION OF 1,1,1,2,2,3,3-HEPTAFLUOR-3-METHOXYPROPANE AND 1-CHLORO-3,3,3-TRIFLUORPROPENE
HUE048024T2 (hu) Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
PL2899247T3 (pl) Kompozycje zawierające 2,3,3,3-tetrafluoropropen i węglowodory oraz ich zastosowania
IL200660A (en) Methods for producing 2,1-propanediol and e. coli is adapted to use these methods
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
IL184554A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EP2220074A4 (en) 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
ZA200800408B (en) Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2008121386A3 (en) Calcimimetic compounds for use in the treatment of bowel disorders
EP2226407A4 (en) METHOD FOR MANUFACTURING METALLIC FILM, METALLIC FILM, AND USE OF METALLIC FILM
BRPI0810560A2 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida.
PL2266619T3 (pl) Kompozycja farmaceutyczna na bazie środków chroniących wątrobę i środków prebiotycznych, ich wytwarzanie i zastosowanie
WO2009014770A3 (en) Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
PL2168584T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację triazolobenzodiazepiny i selektywnego inhibitora wychwytu zwrotnego serotoniny
ZA201002868B (en) Substituted octane(ene) nitriles,methods for the synthesis thereof and uses thereof in perfumery
ZA200802774B (en) Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake
IL201430A0 (en) Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep related breathing disorders
ES2389424B1 (es) Procedimiento para la visualizacion de superficies en el cuerpo humano.
WO2010129788A3 (en) Uses of cationic hydroxythylcellulose in oral ingestion forms, and prevention and treatment of metabolic disorders
HUP0700710A2 (en) Fire resistant liquid, method for the production and use thereof
SI2117533T1 (sl) Farmacevtski sestavek na osnovi stachytarpheta sp., postopek za pridobivanje le-tega, in njegova uporaba za zdravljenje vitiliga
WO2009111031A3 (en) Methods of treating vasomotor symptoms